Skip to Content

Severin Schwan to Succeed Franz B. Humer as Chief Executive of theRoche Group at the March 2008 Shareholders' Meeting

Severin Schwan to succeed Franz B. Humer as Chief Executive of the Roche Group at the March 2008 shareholders' meeting Franz B. Humer to concentrate on role as Chairman

BASEL, Switzerland, July 19, 2007-Roche announced today that Severin Schwan, currently CEO of Roche Diagnostics, will succeed Franz B. Humer as Chief Executive of the Roche Group at the next annual shareholders' meeting on 4 March 2008. Dr. Humer will focus on his role as Chairman of Roche Holdings. Severin Schwan's successor as CEO of Roche Diagnostics will be announced in due course.

In a statement Franz B. Humer said, "In view of the increasing complexity of the tasks involved, the Board has decided to separate the Chairman and CEO roles. I am delighted that we are appointing Severin Schwan, a 40 year-old executive with an outstanding track record and broad international experience at both corporate and divisional level, as the new CEO. As Chairman I will continue to work with the Board and Executive Committee to continue building Roche into a leading global healthcare corporation."

Franz Humer can look back on a 30-year career in the pharmaceutical industry. Between 1973 and 1981 he held positions at Schering Plough as General Manager in Ecuador, the UK and Portugal. He then joined Glaxo to head its regional organisation for Southern Europe, the start of a 14-year career that also saw him serve as head of marketing before becoming Chief Operating Officer. In 1995 he moved to Roche as head of the Pharmaceuticals Division. Humer was appointed Chief Operating Officer in 1996, CEO of the Roche Group in 1998 and Chairman of Roche Holding in 2001. He is a member of the boards of Allianz AG and Diageo Plc and of the JPMorgan International Council. Today Diageo Plc announces separately that Humer will become chairman of the board of that company on 1 July 2008.

Severin Schwan was born in 1967 and is an Austrian citizen. After obtaining a degree in economics and a doctorate in law, Schwan began his career in 1993 at Roche Basel as a finance officer. Following management postings to Germany and Belgium, he became head of Roche Diagnostics' global finance organisation before being named head of the division's Asia-Pacific organisation. In January 2006 Severin Schwan was appointed CEO of Roche Diagnostics , the Roche Group's global diagnostics business. He is married and has three children.

About Roche Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As one of the world's biggest biotech companies and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is one of the world leaders in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006 sales by the Pharmaceuticals Division totalled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai.

Additional information:

Roche Group Media Office Phone: +41 61 688 8888 / e-mail: - Daniel Piller (Head of Roche Group Media Office) - Baschi Dürr - Martina Rupp - Claudia Schmitt

F. Hoffmann-La Roche Ltd Corporate Communications Grenzacherstrasse 124 4070 Basel, Switzerland

Phone: +41 61 68 88888 Fax: +41 61 68 82775

Posted: July 2007